MAIA Biotechnology granted European patent covering ateganosine-based telomere-targeting anticancer therapy

MAIA Biotechnology, Inc.

European Patent Office grants patent for ateganosine-based analogues for telomere-targeting anticancer therapy.
Patent titled 'Mercaptopurine Ribonucleoside Analogues for Altering Telomerase Mediated Telomere'; invented by CSO Sergei Gryaznov and SAB member Jerry Shay.
MAIA's global IP portfolio now includes 10 issued patents worldwide, validated in 19 European countries, and 24 pending applications.
Next-generation telomere-targeting agents aim to improve specificity toward cancer cells and increase anticancer activity.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.